FDA Issues Rebuttal to AstraZeneca Exclusivity Suit

AstraZeneca’s lawsuit against the FDA over the exclusivity of one of its drugs is a “transparent” effort to stifle generic competition for the blockbuster anti-cholesterol drug Crestor, the FDA said in its response to the suit.
Source: Drug Industry Daily